Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)

Phase 1

Completed

• Conditions: Adrenal Tumors; Adrenal Malignancies; Electrolytes Abnormalities; Abnormal Hormonal Secretions
• Interventions: Procedure: Imaging, Adrenal acans; Radiation: (NP-59)

• Registration Number: NCT00591643
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

The purpose of this study is to find out if your adrenal glands are normal or abnormal. This can be determined by whether or not your adrenal gland concentrates more of a labeled building block of adrenal hormone, norcholesterol. This labeled material had been used as an investigative diagnostic tool for imaging adrenal glands for many years with success in our hands. This is a diagnostic procedure. CT, MRI and Ultrasound can determine the size and presence or absence of tumor but cannot assess the function of the adrenal glands. To determine hormone concentrations from blood samples would involve more invasive catherization.

Detailed Description

To investigate the feasibility of using NP-59 to localize adrenal tumors and assess their functions under the influence of pharmacological manipulations.

Study Timeline

• Study Start: 1977-07
• Study First Submitted: 2007-12-26
• Study First Submitted QC: 2007-12-26
• Study First Posted: 2008-01-11
• Primary Completion: 2011-03
• Study Completion: 2011-03
• Status Verified: 2015-12
• Last Update Submitted: 2015-12-23
• Last Update Posted: 2015-12-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 93

Inclusion Criteria

• Patient with clinical and laboratory suspicions of hypersecretion of adrenal cortical hormones

Read More

Exclusion Criteria

• n/a

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Imaging, Adrenal acans & Radiation	(NP-59)	-
Imaging, Adrenal acans & Radiation	Imaging, Adrenal acans	-

Primary Outcome Measures

Name	Time	Method
To investigate the feasibility of using NP-59 to localize adrenal tumors and assess their functions under the influence of pharmacological manipulations.	1 year

Trial Locations

Locations (1)

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States